Company intelligence / Profile preview

Biomason

Durham, North Carolina, United Statesbiomason.com ↗

Ownership: Private
Employees: ~51
Development stage: Other

Overview

Biomason has developed and commercialized biocement products that use non-modified bacteria to grow cement-like materials at ambient temperatures. These products have been installed in the US and Europe. The company’s technology reduces cradle-to-gate carbon emissions by more than 90% compared to traditional Portland cement[7][8]. The first full-scale factory was commissioned in Denmark in 2023[5]. Products include tiles, pavers, walls; additional applications are under development[6]. No clinical results as this is not a healthcare/therapeutic company.

Industry: Non-Drug Biotech

Partnerships

IBF (largest precast concrete producer in Denmark)H&M Group for tile developmentAFRL/DARPA/U.S. Army SBIR contracts for military infrastructure applicationsFRONT Inc. for BioBasedTile® launch in Europe[5][10]

Beyond the preview

Go deeper on Biomason.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biomason.

Explore the full profile